Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00097721 · ClinicalTrials.gov registry record · Phase 2

A Study of E7389 in Advanced/Metastatic Breast Cancer Patients

A Phase 2 study, sponsored by Eisai.

Completed
Registry status
Phase 2
Development phase
104
Enrollment target

NCT00097721: Completed Phase 2 study, sponsored by Eisai.

NCT00097721 is a Phase 2 study that has completed, run by Eisai. The registered enrollment target is 104 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (22% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00097721, a Phase 2 study, has completed, sponsored by Eisai.

COMPLETED
Registry status
Phase 2
Development phase
104 participants
Enrollment target

Study Summary

The purpose of this study is to determine if E7389 is a safe and effective treatment for advanced/metastatic breast cancer.

Primary Outcome

Defined as the percentage of subjects with CR or PR from the start of treatment until disease progression or recurrence. Lesions measured by computed tomography (CT) scan and magnetic resonance imaging (MRI). Objective response rate: complete response (CR-disappearance of all lesions)+ partial response (PR-30% decrease in lesion diameter), Progressive Disease (PD-20% increase in lesion diameter), stable disease (SD-neither shrinkage nor increase of lesions).

Interventions

  • DRUG E7389

Trial Details

FieldValue
Enrollment Target 104 participants
Start Date 2004-09
Est. Completion 2006-11
Phase Phase 2
Eisai

287 total trials

What the finished NCT00097721 record still lists

NCT00097721 is an interventional study that assigns participants to a tested intervention. The registered 104 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (22% lower).

The record links to 0 conditions, and to 1 intervention - of which E7389 is the first listed.

NCT00097721 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00097721 about?

NCT00097721 is a clinical study titled "A Study of E7389 in Advanced/Metastatic Breast Cancer Patients". The purpose of this study is to determine if E7389 is a safe and effective treatment for advanced/metastatic breast cancer.

What is the current status of trial NCT00097721?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 104 participants. The study started on 2004-09. Estimated completion is 2006-11.

What interventions are being tested in trial NCT00097721?

The interventions under investigation include: E7389 (DRUG).

Who is sponsoring clinical trial NCT00097721?

This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00097721's enrollment target sits among peer trials

104 660th of 2000 higher than 1,337 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03403686 · 104 participants

    Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)

  • NCT04228367 · 104 participants · NA

    JuggerStitch Post Market Clinical Follow-up Study

  • NCT04268849 · 104 participants · Phase 3

    Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient

  • NCT04390724 · 104 participants

    Optimizing Y90 Therapy for Radiation Lobectomy

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00097721, the US trial registry maintained by the National Library of Medicine. NCT00097721 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.